EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population

Min J Kim, Isiah Gonzalez, Nia M Choi, David Y Graham, Hashem B El-Serag, Mimi C Tan iD

Helicobacter · 2025-11 · 30 (6)

DOI: 10.1111/hel.70095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Helicobacter, online erschienen am 08.12.2025. Verfasst von Min J Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Emigrants and Immigrants, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Helicobacter pylori infections are mostly treated empirically (without antibiotic susceptibility testing). Determining eradication rates of different treatment regimens can inform antibiotic resistance. Our aim was to examine eradication rates of empiric H. pylori treatments based on treatment regimen, race/ethnicity and previous treatment status in a multiethnic U.S. population. Materials and Methods This was a retrospective cross‐sectional study of patients with a positive H. pylori test from 7/2021 to 4/2022 at Harris Health (Houston, Texas) who had received treatment and eradication testing within 1 year. We compared eradication rates based on treatment regimen, race/ethnicity, and prior treatment and examined other possible risk factors for treatment failure using logistic regression models.

Results

Among 1106 H. pylori ‐infected patients, 29.2% were male, 80.6% Hispanic, 10.7% black, 2.5% white, and 83.3% were non‐U.S. born with a mean age of 50.8 years (standard deviation 12.6). Most patients (57.3%) received bismuth‐tetracycline‐metronidazole quadruple, 21.2% clarithromycin‐metronidazole‐amoxicillin quadruple, 15.6% clarithromycin‐amoxicillin triple, and 3.9% received clarithromycin‐metronidazole triple therapies. Eradication rates were highest for bismuth‐tetracycline‐metronidazole quadruple (83.8%), clarithromycin‐metronidazole‐amoxicillin quadruple (80.3%), and clarithromycin‐amoxicillin triple therapies (79.2%). In 186 (16.8%) previously treated patients, all empiric regimens achieved < 80% eradication rates. Clarithromycin‐amoxicillin triple had high eradication rates (92.9%) in black patients and bismuth quadruple therapy in Asians (95.8%). Compared to bismuth quadruple therapy, clarithromycin‐metronidazole triple (adjusted odds ratio [adjOR] 0.31, 95% confidence interval [CI] 0.13–0.73) and levofloxacin‐amoxicillin triple (adjOR 0.20, 95% CI 0.05–0.89) regimens were associated with treatment failure, whereas clarithromycin‐amoxicillin quadruple and triple therapies were not.

Conclusions

Empiric bismuth quadruple therapy had the highest eradication rate while metronidazole and levofloxacin triple therapies had the lowest. Eradication rates may thus serve as a surrogate clinical endpoint when choosing empiric therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsEmigrants and ImmigrantsHelicobacter InfectionsHelicobacter pyloriAdultAgedFemaleHumansMaleMiddle AgedClarithromycinCross-Sectional StudiesDrug Therapy, CombinationEthnicityMetronidazoleRetrospective StudiesTexasUnited StatesRacial Groups

Stichwörter der Autor:innen

Helicobacter pyloriempiric therapieseradication ratetreatment failure

Substanzen

Anti-Bacterial AgentsClarithromycinMetronidazole

Autor:innen und Institutionen

  • Baylor College of Medicine, Houston, Texas, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Mimi C Tan

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • U.S. Department of Veterans Affairs
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health

Zitieren

APA

Kim, M. J., Gonzalez, I., Choi, N. M., Graham, D. Y., El-Serag, H. B., & Tan, M. C. (2025). Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population. Helicobacter, 30(6). https://doi.org/10.1111/hel.70095

Vancouver

Kim MJ, Gonzalez I, Choi NM, Graham DY, El-Serag HB, Tan MC. Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population. Helicobacter. 2025;30(6). doi:10.1111/hel.70095

BibTeX
@article{Kim2025,
  author = {Kim, Min J and Gonzalez, Isiah and Choi, Nia M and Graham, David Y and El-Serag, Hashem B and Tan, Mimi C},
  title = {Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population},
  journal = {Helicobacter},
  year = {2025},
  volume = {30},
  number = {6},
  doi = {10.1111/hel.70095}
}
Kostenlos starten →